Hemlibra 
Procedural steps taken and scientificw information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0037 
B.II.e.5.c - Change in pack size of the finished 
09/11/2023 
SmPC, 
Annex I has been updated to include the new presentation 
product - Change in the fill weight/fill volume of 
Labelling and 
in the qualitative and quantitative composition section as 
sterile multidose (or single-dose, partial use) 
parenteral medicinal products, including 
biological/immunological medicinal products 
PL 
follows: 
Each vial of 0.4 mL contains 12 mg of emicizumab at a 
concentration of 30 mg/mL. 
To include nature and content of container as follows: 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
3 mL clear glass type I vial with butyl rubber stopper 
laminated with a fluoro-resin film and crimped with an 
aluminium cap fitted with a plastic flip-off disk. Each vial 
contains 12 mg emicizumab in 0.4 mL of solution for 
injection. Each carton contains one vial. 
To include marketing authorization section as follows: 
Hemlibra 30 mg/mL solution for injection 
EU/1/18/1271/006 (12 mg/0.4 mL) 
The Labelling and PL have been updated accordingly.  
Enclosure colour used to differentiate the presentations 
have been added into section 6.5 in line with SmPC 
guideline. 
Changes are also made to the Package Leaflet to bring it in 
line with SmPC and the current QRD template (i.e, inclusion 
of statement “Not all pack sizes may be marketed” in 
section 6). 
In addition, the list of local representatives in the PL is 
being revised. 
Page 2/13 
IB/0039/G 
This was an application for a group of variations. 
09/10/2023 
n/a 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.d.2.d - Change in test procedure for the finished 
 
 
 
 
 
 
 
 
product - Other changes to a test procedure 
(including replacement or addition) 
IB/0038/G 
This was an application for a group of variations. 
09/10/2023 
n/a 
A.z - Administrative change - Other variation 
B.II.b.4.f - Change in the batch size (including batch 
size ranges) of the finished product - The scale for a 
biological/immunological medicinal product is 
increased/decreased without process change (e.g. 
duplication of line) 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
IA/0036/G 
This was an application for a group of variations. 
12/06/2023 
n/a 
A.7 - Administrative change - Deletion of 
Page 3/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
PSUSA/10668
Periodic Safety Update EU Single assessment - 
08/06/2023 
n/a 
PRAC Recommendation - maintenance 
/202211 
emicizumab 
IA/0035 
A.7 - Administrative change - Deletion of 
15/05/2023 
manufacturing sites 
II/0033 
B.II.e.5.c - Change in pack size of the finished 
02/03/2023 
product - Change in the fill weight/fill volume of 
sterile multidose (or single-dose, partial use) 
parenteral medicinal products, including 
biological/immunological medicinal products 
Annex II and 
PL 
SmPC, 
Labelling and 
PL 
II/0027 
Extension of indication to include routine prophylaxis 
15/12/2022 
23/01/2023 
SmPC and PL 
Please refer to Scientific Discussion ‘Hemlibra-H-C-4406-II-
27’ 
of bleeding episodes in adult and paediatric patients 
with haemophilia A (congenital factor VIII deficiency) 
without factor VIII inhibitors who have moderate 
disease (FVIII ≥ 1% and ≤ 5%) with severe bleeding 
phenotype. Hemlibra can be used in all age groups. 
Consequently, sections 4.1, 4.8, 5.1 and 5.2 of the 
SmPC and Section 1 of the package leaflet are 
updated. In addition, Section 4.2 is updated to make 
it clear that the maintenance dose for Hemlibra 
applies from week 5 of dosing. The PIL is updated 
accordingly. Version 4.7 of the RMP has also been 
submitted. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Page 4/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Addition of a new therapeutic indication or 
modification of an approved one 
R/0032 
Renewal of the marketing authorisation. 
21/07/2022 
15/09/2022 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II and Labelling 
the CHMP considered that the benefit-risk balance of 
Hemlibra in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
PSUSA/10668
Periodic Safety Update EU Single assessment - 
10/06/2022 
n/a 
PRAC Recommendation - maintenance 
/202111 
emicizumab 
II/0029/G 
This was an application for a group of variations. 
05/05/2022 
15/09/2022 
Annex II 
The Annex IIA has been updated to add the following site 
B.I.a.1.g - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a new manufacturer of the AS that is 
not supported by an ASMF and requires significant 
update to the relevant AS section in the dossier 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
as a manufacturer of the biological active substance:  
F. Hoffmann La Roche Ltd. 
Grenzacherstrasse 124 
4070 Basel 
Switzerland 
Page 5/13 
 
 
 
 
 
 
 
 
 
 
 
IB/0031 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
20/04/2022 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
II/0028 
C.I.13 - Other variations not specifically covered 
10/03/2022 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
II/0025 
Update of sections 4.4, 4.8 and 5.1 of the Product 
10/03/2022 
15/09/2022 
SmPC, 
Update of the Product Information and RMP to inform HCPs 
information concerning immunogenicity and loss of 
Labelling and 
that unexpected bleeding symptoms while on emicizumab 
efficacy due to anti-emicizumab antibodies. The RMP 
PL 
suggest the possibility of an antidrug antibody (with 
(v.4.1) is proposed to be updated accordingly. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
frequency uncommon). This is based on pooled data from 7 
Phase III Clinical trials (BH29884, BH29992, BH30071, 
BO39182, YO39309, JO39881, and MO39129). 
For more information, please refer to the Summary of 
Product Characteristics. 
II/0026 
Update of section 4.8 of the SmPC to include new 
28/10/2021 
15/09/2022 
SmPC and PL 
The product information has been updated to include the 
data related to hypersensitivity, in compliance with 
the PRAC recommendation following the assessment 
of PSUSA/00010668/202011. The PIL is updated in 
accordance with the changes to the SmPC. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
II/0023/G 
This was an application for a group of variations. 
16/09/2021 
n/a 
1. B.I.a.1.g (Type II) - To add Chugai Pharma 
following ADRs from postmarketing surveillance: 
Angioedema (uncommon), urticaria (common) and rash 
(common) 
Page 6/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Manufacturing Co, Ltd, 5-1, Ukima 5-Chrome, Kita-
Ku-Tokyo 115-8543, Japan as an alternative site 
responsible for the manufacturing, testing and 
storage of the active substance emicizumab.  
2. B.I.a.1.f (Type IB) - To add BioReliance Ltd, Todd 
Campus, West of Scotland Science Park, Glasgow, 
G20 OXA UK as an alternative in-process control 
(IPC) testing site responsible for the mycoplasma 
testing of the preharvest cell culture fluid (PHCCF).  
3. B.I.a.1.f (Type IB) - To add Chugai Pharma 
Manufacturing, Co., Ltd. 116-3, Kiyohara 
Kogyodanchi, Utsunomiya City, Tochigi 321-3231 
Japan (UT) as an alternative in-process control (IPC) 
testing site responsible for the mycoplasma testing 
of the preharvest cell culture fluid (PHCCF).  
4. B.I.a.1.f (Type IB) - To add Charles River 
Laboratories, Inc. 466 Devon Park Drive, Wayne, PA 
19406 USA as an alternative in-process control (IPC) 
testing site responsible for the virus testing of the 
preharvest cell culture fluid (PHCCF).  
5. B.I.a.3.a (Type IB) - To increase the batch size of 
the active substance emicizumab manufactured at 
Chugai Ukima Building W40, Japan from 2000 L to 
6000 L. 
6. B.I.a.4.c (Type IB) - To delete the non-significant 
in-process test for Leptospira applied during the 
manufacture of the active substance emicizumab at 
Page 7/13 
 
 
 
 
 
 
 
 
 
 
Chugai Ukima Building W40, Japan.  
7. B.I.c.1.c (Type IB) - Change in the quantitative 
composition of the immediate packaging of the active 
substance emicizumab.  
In addition, the Marketing Authorisation Holder 
(MAH) has taken the opportunity to update sections 
of Module 3. 
B.I.a.1.g - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a new manufacturer of the AS that is 
not supported by an ASMF and requires significant 
update to the relevant AS section in the dossier 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
Page 8/13 
 
 
 
 
 
 
 
 
increase compared to the originally approved batch 
size 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.c.1.c - Change in immediate packaging of the AS 
- Liquid ASs (non sterile) 
N/0024 
Minor change in labelling or package leaflet not 
10/08/2021 
15/09/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
II/0021 
Submission of an updated RMP version 2.6 in order 
08/07/2021 
n/a 
to add thromboembolic events without concomitant 
aPCC as an important potential risk in the safety 
specifications and to update the milestones for 
BO40853/SURVEY study following approval of the 
protocol v3 (via MEA PRO 002.2). 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
PSUSA/10668
Periodic Safety Update EU Single assessment - 
10/06/2021 
n/a 
PRAC Recommendation - maintenance 
/202011 
emicizumab 
PSUSA/10668
Periodic Safety Update EU Single assessment - 
14/01/2021 
n/a 
PRAC Recommendation - maintenance 
/202005 
emicizumab 
Page 9/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0020 
B.II.f.1.a.1 - Stability of FP - Reduction of the shelf 
07/12/2020 
18/08/2021 
SmPC 
life of the finished product - As packaged for sale 
IB/0017 
B.IV.1.a.1 - Change of a measuring or administration 
19/08/2020 
18/08/2021 
SmPC and PL 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
IB/0018 
B.II.b.2.z - Change to importer, batch release 
28/07/2020 
n/a 
arrangements and quality control testing of the FP - 
Other variation 
PSUSA/10668
Periodic Safety Update EU Single assessment - 
11/06/2020 
n/a 
PRAC Recommendation - maintenance 
/201911 
emicizumab 
IB/0015 
C.I.z - Changes (Safety/Efficacy) of Human and 
19/12/2019 
23/01/2020 
SmPC 
Veterinary Medicinal Products - Other variation 
PSUSA/10668
Periodic Safety Update EU Single assessment - 
28/11/2019 
n/a 
PRAC Recommendation - maintenance 
/201905 
emicizumab 
IB/0013/G 
This was an application for a group of variations. 
09/07/2019 
n/a 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
Page 10/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0012/G 
This was an application for a group of variations. 
21/06/2019 
n/a 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
PSUSA/10668
Periodic Safety Update EU Single assessment - 
14/06/2019 
n/a 
PRAC Recommendation - maintenance 
/201811 
emicizumab 
IB/0011 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
11/04/2019 
23/01/2020 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
II/0002 
Extension of Indication to include routine prophylaxis 
31/01/2019 
11/03/2019 
SmPC, 
Please refer to Scientific Discussion Hemlibra-H-C-4406-II-
Labelling and 
02 
PL 
of bleeding episodes in patients with severe 
haemophilia A (congenital factor VIII deficiency, 
FVIII<1 %) without FVIII activity; as a consequence, 
sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are 
updated with efficacy and safety information of the 
pivotal trials. In addition, the Marketing authorisation 
holder (MAH) took the opportunity to introduce 
minor corrections and clarity to sections 4.4, 4.5 and 
4.6 of the SmPC. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
Page 11/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10668
Periodic Safety Update EU Single assessment - 
13/12/2018 
14/02/2019 
SmPC 
Refer to Scientific conclusions and grounds recommending 
/201805 
emicizumab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10668/201805. 
IB/0008 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
25/10/2018 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0007 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
22/10/2018 
14/02/2019 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IB/0005 
B.IV.1.a.1 - Change of a measuring or administration 
23/08/2018 
14/02/2019 
SmPC, 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
Labelling and 
PL 
N/0006 
Minor change in labelling or package leaflet not 
09/08/2018 
14/02/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0003/G 
This was an application for a group of variations. 
07/06/2018 
n/a 
B.II.b.2.z - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Other variation 
B.II.g.5.c - Implementation of changes foreseen in 
an approved change management protocol - For a 
biological/immunological medicinal product 
Page 12/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T/0001 
Transfer of Marketing Authorisation 
16/04/2018 
30/04/2018 
SmPC, 
Labelling and 
PL 
Page 13/13 
 
 
 
 
 
 
 
 
